Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.

by Thomas Celona

The Cancer Today editors share the most impactful reporting on cancer research from 2024.

by Cancer Today staff

From the Editor-in-Chief

A recently approved therapy targets abnormal enzymes produced by gene defects.

by William G. Nelson, MD, PhD

Forward Look

More patients are receiving CAR T-cell therapy for large B-cell lymphoma.

by Leah Lawrence

Forward Look

Researchers and patients push to move away from maximum tolerated dose in research.

by Natalie Slivinski

Shorter courses of more intense radiation therapy mean fewer visits and less cost for patients. Studies show abbreviated treatments are just as effective as longer courses.

by Stephen Ornes

With targeted therapy options available for a growing number of cancer types, biomarker testing is making a difference for more people with solid cancers.

by Kendall K. Morgan

Geriatric assessments can help physicians and older patients choose effective treatments with fewer side effects.

by Eric Fitzsimmons

Q&A

Journalist Lawrence Ingrassia traces the scientific history of a genetic disorder that predisposes families like his to cancer.

by Thomas Celona

Forward Look

Androgen deprivation therapy, a common prostate cancer treatment, may increase cognitive difficulties.

by Joseph Jalkiewicz